U.S Subsidiary of CanniMed Therapeutics bids for State of Michigan License to Produce and Process Medical Cannabis

CanniMed Therapeutics Inc’s wholly owned subsidiary Sub Terra LLC moves to produce and process medical cannabis through its State of Michigan licenses application. The company has further intended to apply for a class C Grower license and processor license given the assent of the municipal from Carp lake township, Michigan. Depending on the implication, the company also attempts to embark on medical cannabis research in accordance with  the U.S Food and Drug Administration and the Drug enforcement administration.

Bid to bolster the company’s plan to expedite pharmaceutical drug approval for cannabis-based medicine in the U.S. The government approved application will ensure a noteworthy foothold in the U.S Market where the company strategically desires to target. Production of medical cannabis will be in line with with its existing growth chamber technology. 15,000 sq.ft underground expansion at the Sub Terra Facility commences in 2018 after which four additional licenses set to be applied for. The company plans to remarkably increase the number of employees once the  expansion takes place that is likely to be completed in 2019.

Brent Zettl, President and CEO of CanniMed states “This application to the State of Michigan demonstrates our continuing focus and leadership towards legally producing medical cannabis in the United States”.

Sub terra LLC is mainly a plant based pharmaceutical manufacturer located in white pine, Michigan that produces proteins and phytochemicals using eco-friendly technologies in a bio-secure underground environment posing innumerable advantages like all crops grown in a controlled environment ensuring acute growth potential and success complying with top-notch standards yielding on a persistent basis. No usage of pesticides and herbicides implies disease-free plants thus combating external threats.

CanniMed assures to adhere to all federal policies and laws as far as production of cannabis in the united States is concerned. Hence, refuting to commence production unless the required state licenses are obtained.  As of now a federal research license has been received.